Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-na?ve patients with metastatic castration-resistant prostate cancer.
Massoudi M, Balk M, Yang H, Bui CN, Pandya BJ, Guo J, Song Y, Wu EQ, Brown B, Barlev A, Flanders S. Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-na?ve patients with metastatic castration-resistant prostate cancer. J Med Econ. 2017 Feb; 20(2):121-128.